Mylan Laboratories has signed an agreement with Gilead Sciences to increase access to Tenofovir Alafenamide (TAF) based HIV treatments in developing countries.
Mylan received non-exclusive rights to manufacture and distribute TAF as both a single agent product and in combination with other drugs.
According to the company, TAF is an investigational antiretroviral drug for the treatment of HIV-1 infection.
Mylan CEO Heather Bresch said: "Mylan's mission is to provide the world's seven billion people access to high quality medicines and set new standards in health care.
"By working with partners like Gilead to help ensure access to innovative new products such as Tenofovir Alafenamide (TAF) in the countries hardest hit by this disease, we can help stem the tide of HIV / AIDS around the world."
Mylan will receive technology transfer from Gilead following US Food and Drug Administration (FDA) approval for the drug, as part of the licensing agreement.
The agreement enables the company to manufacture low-cost versions of TAF for developing markets, if approved as a single agent or in approved combinations containing TAF.
The deal allows Mylan to distribute TAF in 112 countries, providing treatment to 30 million HIV patients, representing 84% of those infected globally.
Mylan noted that Gilead's Phase III trials met their primary objective, supporting the potential for TAF to provide a new treatment option for individuals living with HIV.